Table of Contents | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------- ...

Vertex Pharmaceuticals Incorporated (VRTX) reported adjusted earnings of $4.38 per share for the third quarter of 2024, surpassing the Zacks Consensus Estimate of $4.13. In the year-ago quarter, the company had recorded adjusted earnings of $4.08 per share. Earnings grew year over year owing to increased product revenues.The company reported total revenues of $2.77 billion for the third quarter, comprising cystic fibrosis (CF) product revenues. The figure beat the Zacks Consensus Estimate of $2.67 billion. ...

THIRD QUARTER 2024 FINANCIAL RESULTS ©2024 Vertex Pharmaceuticals Incorporated VERTEX NOVEMBER 4, 2024 AGENDA Introduction Susie Lisa, CFA, Senior Vice President, Investor Relations CEO Perspective and Pipeline Update Reshma Kewalramani, M.D., Chief Executive Officer and President Commercial Update Stuart Arbuckle, Executive Vice President and Chief Operating Officer Financial Results Charlie Wagner, Executive Vice President and Chief Financial Officer ©2024 Vertex Pharmaceuticals Incorporated 2 SAFE HARBOR ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Dr. Reshma Kewalramani - President and CEO Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer Conference Call Participants Jessica Fye - J.P. Morgan Salveen Richter - Goldman Sachs Chris Garcia - Morgan Stanley Mohit Bansal - Wells Fargo Tazeen Ahmad - Bank of America Michael Yee - Jefferies ...

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $4.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.05%. A quarter ago, it was expected that this drugmaker would post a loss of $11.50 per share when it actually produced a loss of $12.83, delivering a surprise of -11.57%.Over the last four quarters, the c ...

Vertex Reports Third Quarter 2024 Financial Results — Product revenue of $2.77 billion, a 12% increase compared to Q3 2023 — — Raising full-year product revenue guidance to $10.8 billion to $10.9 billion — — Preparing for two potential near-term launches: vanzacaftor triple in CF and suzetrigine (VX-548) for moderate-to-severe acute pain — — Pipeline progress continuing with three additional programs advancing to Phase 3: suzetrigine in DPN, povetacicept in IgAN and VX-880 in T1D — BOSTON -- Vertex Pharmace ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $475.08, with a +1% movement compared to the previous day. The stock exceeded the S&P 500, which registered a loss of 0.33% for the day. At the same time, the Dow lost 0.22%, and the tech-heavy Nasdaq lost 0.56%.Heading into today, shares of the drugmaker had gained 0.13% over the past month, outpacing the Medical sector's loss of 4.31% and lagging the S&P 500's gain of 1.83% in that time.Investors will be eagerly watching for the performance ...

In its upcoming report, Vertex Pharmaceuticals (VRTX) is predicted by Wall Street analysts to post quarterly earnings of $4.13 per share, reflecting an increase of 1.2% compared to the same period last year. Revenues are forecasted to be $2.68 billion, representing a year-over-year increase of 7.8%. The consensus EPS estimate for the quarter has been revised 1.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial e ...

Vertex Pharmaceuticals (VRTX) closed at $476.37 in the latest trading session, marking a -0.28% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.27%. Meanwhile, the Dow experienced a rise of 0.65%, and the technology-dominated Nasdaq saw an increase of 0.26%.Shares of the drugmaker witnessed a gain of 3.2% over the previous month, beating the performance of the Medical sector with its loss of 4.14% and the S&P 500's gain of 2%.Market participants will be closely fol ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $478.09, reflecting a -1.02% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.18% loss on the day. At the same time, the Dow lost 0.8%, and the tech-heavy Nasdaq gained 0.27%.Prior to today's trading, shares of the drugmaker had gained 3.89% over the past month. This has outpaced the Medical sector's loss of 3.03% and lagged the S&P 500's gain of 4.46% in that time.Market participants will ...